JAK1 inhibitors
US-9556153-B1 · Jan 31, 2017 · US
Pyrazolylaminobenzimidazole derivatives as JAK inhibitors
US10344018B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10344018-B2 |
| Application number | US-201916273706-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 12, 2019 |
| Priority date | Jul 14, 2016 |
| Publication date | Jul 9, 2019 |
| Grant date | Jul 9, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides compounds of the formula below (I′): where R, and R1-R3 are as described herein, methods of treating patients for certain types of autoimmune diseases and cancer, and processes for preparing the compounds.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound of the formula, or a pharmaceutically acceptable salt thereof wherein R is —C 1-3 alkyl; R1 is —OCH 3 ; R2 is —CHF 2 or —CF 3 ; and R3 is H or —CH 3 . 2. A compound of the formula, or a pharmaceutically acceptable salt thereof, wherein: R is —C 1-3 alkyl R1 is —OCH 3 ; R2 is —CHF 2 or —CF 3 ; and R3 is H or —CH 3 . 3. A compound according to claim 1 a wherein R is —CH 3 , or —CH 2 CH 3 , or a pharmaceutically acceptable salt thereof. 4. A compound according to claim 3 wherein R2 is —CF 3 , or a pharmaceutically acceptable salt thereof. 5. A compound according to claim 1 which is or a pharmaceutically acceptable salt thereof. 6. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier, diluent or excipient. 7. A method of treating a patient in need of treatment for arthritis wherein the method comprises administering to the patient an effective amount of a compound according to claim 5 , or a pharmaceutically acceptable salt thereof. 8. The compound according to claim 5 which is: 9. A pharmaceutical composition comprising a compound according to claim 5 and a pharmaceutically acceptable carrier, diluent or excipient.
Assignees
Inventors
Classifications
for joint disorders, e.g. arthritis, arthrosis · CPC title
containing three or more hetero rings · CPC title
- A61K31/4184Primary
condensed with carbocyclic rings, e.g. benzimidazoles · CPC title
Drugs for disorders of the alimentary tract or the digestive system · CPC title
containing three or more hetero rings · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10344018B2 cover?
- The present invention provides compounds of the formula below (I′): where R, and R1-R3 are as described herein, methods of treating patients for certain types of autoimmune diseases and cancer, and processes for preparing the compounds.
- Who is the assignee on this patent?
- Lilly Co Eli
- What technology area does this patent fall under?
- Primary CPC classification A61K31/4184. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).